<p><i>The media and technology company makes strategic move to strengthen its leadership team to accelerate revenue growth across sports streaming</i>&nbsp;</p>

Dr. Torrejon, the original founder of Humonix, replaces Kimberly Southern

Darcy Dinga joins the team with a strong technology and operations background.

Specialty pharmaceutical research company’s new retinal vascular dysfunction model can have a major impact on research and development of new drugs for retinal vascular diseases.

A new executive leadership appointment from within the HR technology consulting sphere sets Click Boarding up for further expansion.

Specialty pharmaceutical research company celebrates the launch of a new service offering and with it, a brand refresh.

AmplifyBio is adding manufacturing services, starting with cell therapy and plasmids, to its growing capabilities to support the safe development of advanced therapies.

Pharma industry veterans focus on asset value creation for sponsors

The agreement will drive the discovery of more effective treatments for cardiovascular disease and development of safer drugs with the preclinical implementation of advanced human heart models

New MarketBridge report reveals CROs' struggles and priorities in XaaS channel transformation amid an uncertain economy

Ms. Prymas to lead continued revenue growth and alignment of strategy, as well as oversee strategy for profitable revenue generation over the long term for Smile CDR's global growth

With new product failure at 70%, BoldLabs is changing the paradigm with its fully managed Digital Test Market, predictive analytics, and conversion rate optimization (CRO)

Advanced photonics company continues growth of its team with appointment of Bruce J. Mosley as Chief Revenue Officer

New Executives Join Xevant to Advance Technology and Growth Through the Power of the Xevant Platform.

Former McKinsey and Goldman Sachs Executive to Play Pivotal Role in Expanding Firm's Cross-Market Risk Management Strategy

The in-vitro studies performed in Glauconix's co-culture 3D conventional human outflow model confirm efficacy

3D Human Tissue Retina Vasculature model provides a new and novel approach to rapidly and efficiently screening numerous therapies for diabetic retinopathy and diabetic macular edema.

Providing oncology drug developers with the successful delivery of early phase oncology studies

Winmo Appoints Jim Donovan as CRO to Drive Growth in 2020 & Beyond

Celebrating success across life sciences

New leadership to support business expansion in Colorado and across Western U.S.

This 2019 award sheds light on Iunisov.com's far-reaching expertise in digital marketing and lead generation. These competencies span across Europe and North America for both B2B and B2C companies and include various economy sectors. — Andrei Iunisov, CEO, Iunisov.com

Lotus Clinical Research LLC receives private equity backing; expands team with Jeffrey Kinell and Kurt Brykman joining board of directors

Lotus Clinical Research Presented at Pain Therapeutics in San Francisco on Development of Long-Acting Local Anesthetics

CROs are finding themselves operating in an increasingly competitive market, where true differentiation is hard to achieve. In order to stand out from the competition, today's CROs need to offer something more.

With so much at stake, where do you start when considering the right long-term strategic CRO partner? With technology and the market both priming CROs to step in as industry innovators, what attributes should sponsors look for in 'best-in-class' strategic partners?

George Clinical, leading Asia-Pacific CRO, expands into US with acquisition of a specialised oncology CRO Division.

RxPense®, an intelligent and connected medication management and remote monitoring solution, can significantly increase reliability of clinical trial data by ensuring participants take their doses on time and only when prescribed. CRO's benefit from enhanced and secure data collection, medication security, remote patient monitoring, and vitals reporting at the point of access - all at drastically reduced cost.